What to expect from HER-2 directed therapies in advanced gastric cancer?

被引：1
|
作者：
Dane, Faysal [1 ]
机构：
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Mimar Sinan Caddesi 41 Ust Kaynarca Fevzicakmak M, Istanbul, Turkey
来源：
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 04期
关键词：
Gastric cancer; HER-2/neu; Targeted therapy;
D O I：
10.5472/mmj.87204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 50 条
  • [1] Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
    Kahraman, Seda
    Yalcin, Suayib
    ONCOTARGETS AND THERAPY, 2021, 14 : 4149 - 4162
  • [2] Serum level of HER-2/neu in patients with gastric cancer: Correlation with HER-2/neu overexpression in gastric carcinoma tissue
    Kono, K
    Naganuma, H
    Sekikawa, T
    Amemiya, H
    Takahashi, A
    Iizuka, H
    Matsumoto, Y
    TUMOR BIOLOGY, 2000, 21 (03) : 139 - 144
  • [3] A case of recurrence following comprehensive treatment for advanced gastric cancer with HER-2 amplification
    Zhou, Minghui
    Ye, Minfeng
    Chen, Jia
    Tao, Feng
    ASIAN JOURNAL OF SURGERY, 2024, 47 (01) : 630 - 633
  • [4] HER-2 directed therapies across gastrointestinal tract cancers - A new frontier
    Jones, Lauren
    Cunningham, David
    Starling, Naureen
    CANCER TREATMENT REVIEWS, 2024, 129
  • [5] HER-2 amplification is highly homogenous in gastric cancer
    Marx, Andreas H.
    Tharun, Lars
    Muth, Johanna
    Dancau, Ana-Maria
    Simon, Ronald
    Yekebas, Emre
    Kaifi, Jussuf T.
    Mirlacher, Martina
    Bruemmendorf, Tim H.
    Bokemeyer, Carsten
    Izbicki, Jakob R.
    Sauter, Guide
    HUMAN PATHOLOGY, 2009, 40 (06) : 769 - 777
  • [6] Advanced HER2-positive gastric cancer: Current and future targeted therapies
    Pazo Cid, Roberto A.
    Anton, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 350 - 362
  • [7] HER-2/neu in locally advanced breast cancer
    Quevedo Gutierrez, Karla Malinalli
    Landa Fernandez, Ana Maria
    Garcia Barrera, Victor
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 (03): : 108 - 115
  • [8] HER-2/neu and TOPIIα Expression in Gastric Cancer Reflect Disease Severity
    Liu, Hong-Qi
    Zhang, Shao-Lan
    Song, Shu
    HEPATO-GASTROENTEROLOGY, 2012, 59 (116) : 1290 - 1293
  • [9] Correlations of β-catenin,Ki67 and Her-2/neu with gastric cancer
    Hong-Wen Wu
    Cheng-Yong Qin
    Ji-Lai Huang
    Xian-Yi Kong
    Wen-Ji Wang
    Wen-Kun Bai
    Asian Pacific Journal of Tropical Medicine, 2014, (04) : 257 - 261
  • [10] HER-2 positive gastric cancer: Current targeted treatments
    Malla, Rama Rao
    Nellipudi, Haasita Reddy
    Srilatha, Mundla
    Nagaraju, Ganji Purnachandra
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 274
12345